Checkpoint molecule PD-1-assisted CD8

The aim of this study was to determine whether CD8A total of 231 mRCC patients, from 2007 to 2017, treated with sunitinib or sorafenib in Zhongshan Hospital, Fudan University were included in the study analyses. CD8, PD-1, and PD-L1 was assessed by immunohistochemistry on continuous paraffin-embedded slides. Kaplan-Meier method and COX regression model were applied in the survival analyses.Baseline characteristics were comparable between the training (n=118) and validation (n=113) sets. Patients with high CD8Our findings suggest that abundant CD8